Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
about
Approach to hypohidrosisImpact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.[Guillain-Barré syndrome after exposure to influenza].Campylobacter species and Guillain-Barré syndrome.The effect of myelinating Schwann cells on axons.Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.The immunobiology of Guillain-Barré syndromes.Anti-ganglioside antibodies alter presynaptic release and calcium influxTumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cellsTopology and patch-clamp analysis of the sodium channel in relationship to the anti-lipid a antibody in campylobacteriosis.Novel treatment for immune neuropathies on the horizon.Pathophysiology and diagnosis of Guillain-Barré syndrome - challenges and needs.A rare neurological complication of typhoid fever: Guillain-Barre' syndrome.GM1 ganglioside for acute ischemic stroke. Trial design issues.Chronic immune-related demyelinating neuropathies.Guillain-Barré syndrome. A severe case calling for intensive treatment.Guillain-Barré syndrome in immunocompromised patients: a report of three patients and review of the literature.Treatment of inflammatory neuropathy.Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome.Assessment of autonomic dysfunction in childhood guillain-barré syndrome.Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells.Binding of immunoglobulin G antibodies in Guillain-Barré syndrome sera to a mixture of GM1 and a phospholipid: possible clinical implications.IgG from patients with Guillain-Barré syndrome interact with nicotinic acetylcholine receptor channels.Diagnosis, pathogenesis and treatment of Miller Fisher syndrome and related disorders: clinical significance of antiGQ1b IgG antibody.Granulocyte-colony-stimulating factor treatment enhances Foxp3(+) T lymphocytes and modifies the proinflammatory response in experimental autoimmune neuritis.Differential effects of CXCR4-CXCL12- and CXCR7-CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis.Miller Fisher syndrome with sinus arrest.Disruption and reorganization of sodium channels in experimental allergic neuritis.Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.Experimental sensory neuropathy induced by sensitization with ganglioside GD1b.Epidemiologic features of Guillain-Barré syndrome in São Paulo, Brazil.Guillain-Barré syndrome associated with scrub typhus.Immunopathology and Th1/Th2 immune response of Campylobacter jejuni-induced paralysis resembling Guillain-Barré syndrome in chicken.Nerve biopsy in chronic inflammatory neuropathies: in situ biomarkers.
P2860
Q28277835-2A0DFC11-DAFE-4666-8B6B-1EE185DF58A2Q30252123-8F8B1713-A719-4CD0-AA81-9D92270FDF4AQ30415924-89681991-E514-4BE2-B02E-6C65DFBAFE8AQ33975353-46E1B101-76B2-4ACD-8E0F-470F9CABCCB1Q34194525-E14DAC56-9DA9-43EE-9FBF-AC09BE1DED6AQ34646725-03B03849-7E27-46D2-91AD-5F9CF7B70A3BQ36164122-EDF9D154-83CB-4CA8-9584-93B087843368Q36168575-F9BAB318-7EBA-45B0-A48A-837811EF58BFQ36590206-87FDCAA2-65D6-4E36-8217-9FA322D49103Q37073308-53885784-4992-46ED-8D22-48C74EC42ACAQ37892641-544BF63F-1754-4B2D-B402-EDEB9CF48A8BQ38204498-FB0E48BF-AD39-4E54-BD67-ACC74CD16C80Q40189783-147EFFF4-1C69-4EA0-8233-738C887EC176Q40851013-2AEE9057-A9B4-44FF-8886-617ABE6CEA4DQ40939580-D7C2C13D-1126-4989-8395-81F445143A7BQ41387557-7427F502-2CB0-47D9-96AD-1C0A0FC9A40CQ41543833-FC0FCC0A-2DFD-45D8-BDF5-DD4B316C7DB6Q41589697-163727B8-65C0-49C6-841A-491C6EF259E8Q42462640-E4259239-7E02-45BE-90D1-CE95E334C7D1Q42910709-247186CC-917D-46A9-9C44-95414D008D7BQ42965389-FD803EDC-3975-42F1-8AE0-D470DAAAD2B1Q44360672-828626A1-0F6B-48A5-BFCD-09F5EF9D08ECQ44379502-238A8BEB-12C8-4E92-9BCD-79CBEC9957ECQ44482447-1638E810-3C1F-4F6E-94B6-A22FFED57388Q45334041-02C6E8CD-21DE-482E-A9F8-DEEAD863A2FCQ46288073-F735EEB5-E165-46C5-9606-39148665669DQ47118621-36582743-B39C-4085-8BA5-6E5BBF3EBA90Q47878922-7EFF4AD6-AC07-4CDA-AC19-B0AD71505C37Q48651342-8345982E-CBCE-4648-957F-5B99499A4104Q49045209-4049B071-D97F-4A96-9F47-78BD0F7D0EBEQ50743670-18A9A05C-E54B-4D80-A569-7C71B7B8F43AQ51741763-BC737FFF-8D95-4B17-8851-F43851F01E04Q54338112-B4A5D00D-78B0-4516-89C5-8DB0E3927A39Q54362178-D5816018-36CA-4108-98BF-93DE91D947FD
P2860
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
@en
type
label
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
@en
prefLabel
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
@en
P2093
P2860
P356
P1433
P1476
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
@en
P2093
P2860
P304
P356
10.1002/MUS.880180202
P577
1995-02-01T00:00:00Z